Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Sujay
Kango has joined the company as executive vice president, chief
commercial officer and Winston “K.C.” Lam has joined as executive vice
president, general counsel. Mr. Kango and Mr. Lam each bring more than
20 years of experience in the pharmaceutical industry, including
expertise in oncology and hematology, and have played key roles in
building successful companies and commercial organizations. Both Mr.
Kango and Mr. Lam will report to Adelene Perkins, chair, president and
chief executive officer at Infinity.
K.C. Lam, Executive Vice President, General Counsel (Photo: Business Wire)
“The addition of Sujay to our executive team is an important advancement
for Infinity as we continue to build our commercial capabilities in
preparation for the potential launch of duvelisib,” said Ms. Perkins.
“We look forward to benefitting from Sujay’s experience in both large
and emerging companies, as well as his deep understanding of the
hematology-oncology market.”
“K.C. has an extensive record of legal and corporate development
accomplishments. He will be an outstanding member of our executive
leadership team in helping us achieve our mission of building a fully
integrated biotechnology company with a sustainable pipeline. We are
thrilled to have both Sujay and K.C. join Infinity at this exciting time
in the development of duvelisib and the company,” Ms. Perkins continued.
Prior to joining Infinity, Mr. Kango most recently served as vice
president, global marketing, sales operations (and business analytics)
at Onyx Pharmaceuticals, an Amgen subsidiary, where he led the global
Onyx proteasome inhibitor franchise, including Kyprolis® and
oprozomib and co-chaired the Onyx-Bayer executive committee responsible
for oversight of the companies’ global kinase inhibitor franchise. Prior
to Onyx, he held several leadership positions at Merck & Co., including
vice president, hepatitis franchise and vice president, oncology
integrated business unit. Prior to Merck, Mr. Kango held various
commercial and marketing roles of increasing responsibility at Johnson &
Johnson and Schering-Plough. Mr. Kango earned a B.S. in Microbiology and
an MBA from McNeese State University.
Prior to joining Infinity, Mr. Lam served as executive vice president,
business development and chief legal officer at Caris Life Sciences. In
this role, Mr. Lam was responsible for business development,
reimbursement strategy and medical policy, pharmaceutical services and
legal affairs. Prior to Caris, Mr. Lam served as group vice president
and associate general counsel at Schering-Plough where he served as
chief legal counsel for the Global Pharmaceuticals Business Unit which
represented 75 percent of Schering-Plough’s total revenues. He also
played active roles in the management of the company’s key strategic
alliances and in executing its licensing, merger and acquisition
strategy. Prior to Schering-Plough, Mr. Lam held various roles of
increasing responsibility in business development and law at McKesson
Corporation and at Baxter Healthcare Corporation. He earned a B.A. from
Carleton College, an MBA from University of Chicago, Booth School of
Business and a J.D. from Cornell University Law School.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to
discovering, developing and delivering best-in-class medicines to people
with difficult-to-treat diseases. Infinity combines proven scientific
expertise with a passion for developing novel small molecule drugs that
target emerging disease pathways. For more information on Infinity,
please refer to the company’s website at www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
including those regarding the Company’s expectations about the potential
commercialization of duvelisib, including a potential launch, and the
anticipated contributions of Sujay Kango and Winston “K.C.” Lam. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from the company’s current expectations, including, for
example, that there is guarantee duvelisib will successfully complete
necessary preclinical and clinical development phases, or gain
regulatory approval, that Infinity’s strategic collaboration
with AbbVie will continue, and other risks described in greater detail
under the caption “Risk Factors” included in Infinity’s annual report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on February 24, 2015, and other filings filed by Infinity with the SEC.
Any forward-looking statements contained in this press release speak
only as of the date hereof, and Infinity expressly disclaims any
obligation to update any forward-looking statements, whether as a result
of new information, future events or otherwise.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150414005337r1&sid=ntxv4&distro=nx&lang=en)
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150414005337/en/
Copyright Business Wire 2015